The dual role of pharmacogenetics in HIV treatment: Mutations and polymorphisms regulating antiretroviral drug resistance and disposition

Pharmacological Reviews

Volumn 64, Issue 3, 2012, Pages 803-833

  Michaud, Veronique ^a,b,c   Bar Magen, Tamara ^a,d   Turgeon, Jacques ^c,e   Flockhart, David ^b   Desta, Zeruesenay ^b   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CHEMICAL STRUCTURE; COMORBIDITY; DRUG DISPOSITION; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSPORT; ENZYME ACTIVITY; EPIDEMIC; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLUCURONIDATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIFE CYCLE; LIVER TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS DNA CELL DNA INTERACTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 84930480295     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.111.005553     Document Type: Article

References (369)

1. http://www.cypalleles.ki.se In Ingelman-Sundberg M, Daly AK,Nebert DW. (eds).
2. Abebe A, Demissie D, Goudsmit J, Brouwer M, Kuiken CL, Pollakis G, Schuitemaker H, Fontanet AL, and Rinke de Wit TF (1999) HIV-1 subtype C syncytium-and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 13:1305-1311.
3. Abel S, Jenkins TM, Whitlock LA, Ridgway CE, and Muirhead GJ (2008) Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol 65 (Suppl 1):38-46.
4. Agarwal S, Pal D, and Mitra AK (2007) Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm 339:139-147.
5. Agarwala R, Mohan S, Herlitz LC, and Cheng JT (2010) The case: 41-year-old HIV patient with proteinuria and progressive renal dysfunction. Tenofovir toxicity. Kidney Int 77:475-476.
6. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, and Berger EA (1996) CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958.
7. Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, Zheng JH, Ray M, and MaWhinney S (2009) Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother 64:1071-1079.
8. Anderson PL, Lamba J, Aquilante CL, Schuetz E, and Fletcher CV (2006) Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIVinfected adults: a pilot study. J Acquir Immune Defic Syndr 42:441-449.
9. Andrew A and Strebel K (2010) HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. Mol Aspects Med 31:407-417.
10. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R, et al. (2004) TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 48:4680-4686.
11. Annaert P, Ye ZW, Stieger B, and Augustijns P (2010) Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40:163-176.
12. Antonelli G, Turriziani O, Cianfriglia M, Riva E, Dong G, Fattorossi A, and Dianzani F (1992) Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein. AIDS Res Hum Retroviruses 8:1839-1844.
13. Anttila S, Hukkanen J, Hakkola J, Stjernvall T, Beaune P, Edwards RJ, Boobis AR, Pelkonen O, and Raunio H (1997) Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol 16:242-249.
14. Arab-Alameddine M, Di Iulio J, Buclin T, Rotger M, Lubomirov R, Cavassini M, Fayet A, Décosterd LA, Eap CB, Biollaz J, et al. (2009) Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 85:485-494.
15. Arhel N (2010) Revisiting HIV-1 uncoating. Retrovirology 7:96.
16. Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang XV, Ellis D, et al. (2000) Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 44:2475-2484.
17. Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, Kurowski M, Luber A, Merry C, and Perno CF (2002) Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 16 (Suppl 1):S5-S37.
18. Back D, Sekar V, and Hoetelmans RM (2008) Darunavir: pharmacokinetics and drug interactions. Antivir Ther 13:1-13.
19. Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, and Hekster YA (2001) Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 15:991-998.
20. Bailes E, Gao F, Bibollet-Ruche F, Courgnaud V, Peeters M, Marx PA, Hahn BH, and Sharp PM (2003) Hybrid origin of SIV in chimpanzees. Science 300:1713.
21. Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, and Wainberg MA (2010) Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 84:9210-9216.
22. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, and Bélanger A (2000) 3'-Azido-3'-deoxythimidine (AZT) is glucuronidated by human UDPglucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 28:497-502.
23. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, et al. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-871.
24. Barrios A, García-Benayas T, González-Lahoz J, and Soriano V (2004) Tenofovirrelated nephrotoxicity in HIV-infected patients. AIDS 18:960-963.
25. Bélanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, and Guillemette C (2009) Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 37:1793-1796.
26. Berger EA, Murphy PM, and Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17:657-700.
27. Beutler E, Gelbart T, and Demina A (1998) Racial variability in the UDPglucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95:8170-8174.
28. Bilello JA, Bilello PA, Stellrecht K, Leonard J, Norbeck DW, Kempf DJ, Robins T, and Drusano GL (1996) Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 40:1491-1497.
29. Blanch J, Martínez E, Rousaud A, Blanco JL, García-Viejo MA, Peri JM, Mallolas J, De Lazzari E, De Pablo J, and Gatell JM (2001) Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr 27:336-343.
30. Boden D and Markowitz M (1998) Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 42:2775-2783.
31. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, and Miller V (2003) Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 19:825-835.
32. Boffito M, Maitland D, and Pozniak A (2006) Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies. J Clin Pharmacol 46:130-139.
33. Bonura F, Tramuto F, Vitale F, Perna AM, Viviano E, Romano N, and Group for HIV-1 Antiretroviral Studies in Sicily (2010) Transmission of drug-resistant HIV type 1 strains in HAART-naive patients: a 5-year retrospective study in Sicily, Italy. AIDS Res Hum Retroviruses 26:961-965.
34. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, and Oude Elferink RP (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333:1171-1175.
35. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JM, Goudsmit J, and Larder BA (1992) Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 165:105-110.
36. Bousquet L, Pruvost A, Didier N, Farinotti R, and Mabondzo A (2008a) Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein. Eur J Pharm Sci 35:247-256.
37. Bousquet L, Pruvost A, Guyot AC, Farinotti R, and Mabondzo A (2009) Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation. Antimicrob Agents Chemother 53: 896-902.
38. Bousquet L, Roucairol C, Hembury A, Nevers MC, Creminon C, Farinotti R, and Mabondzo A (2008b) Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier. AIDS Res Hum Retroviruses 24:1147-1154.
39. Boyd MA, Srasuebkul P, Ruxrungtham K, Mackenzie PI, Uchaipichat V, Stek M, Jr., Lange JM, Phanuphak P, Cooper DA, Udomuksorn W, and Miners JO (2006) Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet Genomics 16:321-329.
40. Brady T, Agosto LM, Malani N, Berry CC, O'Doherty U, and Bushman F (2009) HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS 23:1461-1471.
41. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M, and Wainberg MA (2006) HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20:F9-13.
42. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, et al. (2002) Persistence and fitness of multidrugresistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 76:1753-1761.
43. Briz O, Serrano MA, MacIas RI, Gonzalez-Gallego J, and Marin JJ (2003) Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J 371:897-905.
44. Brown KC, Paul S, and Kashuba AD (2009) Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet 48:211-241.
45. Busti AJ, Hall RG, and Margolis DM (2004) Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 24:1732-1747.
46. Cabrera SE, Santos D, Valverde MP, Domínguez-Gil A, González F, Luna G, and García MJ (2009) Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother 53:2791-2798.
47. Campbell SD, de Morais SM, and Xu JJ (2004) Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 150:179-187.
48. Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, and Gianotti N (2009) Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 23:455-460.
49. Carr DF, la Porte CJ, Pirmohamed M, Owen A, and Cortes CP (2010) Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J Antimicrob Chemother 65:1889-1893.
50. Chaudhary PM, Mechetner EB, and Roninson IB (1992) Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80:2735-2739.
51. Chen J, Sun J, Ma Q, Yao Y, Wang Z, Zhang L, Li L, Sun F, and Lu H (2010) CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Ther Drug Monit 32:573-578.
52. Chiba M, Hensleigh M, and Lin JH (1997) Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem Pharmacol 53:1187-1195.
53. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, and Kim RB (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660.
54. Chou M, Bertrand J, Segeral O, Verstuyft C, Borand L, Comets E, Le Tiec C, Becquemont L, Ouk V, Mentre F, et al. (2010) Population pharmacokineticpharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother 54:4432-4439.
55. Chu KM, Boulle AM, Ford N, Goemaere E, Asselman V, and Van Cutsem G (2010) Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa. PLoS One 5:e9183.
56. Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d'Arminio Monforte A, et al. (2010) Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients. HIV Med 11: 104-113.
57. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, et al. (2007) Efficacy and safety of darunavirritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369:1169-1178.
58. Coca S and Perazella MA (2002) Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 324:342-344.
59. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, and Waxman DJ (1997) Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985-993.
60. Coffin JM (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
61. Collier AC, Keelan JA, Van Zijl PE, Paxton JW, Mitchell MD, and Tingle MD (2004) Human placental glucuronidation and transport of 3' azido-3'-deoxythymidine and uridine diphosphate glucuronic acid. Drug Metab Dispos 32:813-820.
62. Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H, Buclin T, Goldstein D, Décosterd L, Telenti A, et al. (2005) Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics 15:599-608.
63. Congiu M, Mashford ML, Slavin JL, and Desmond PV (2002) UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 30:129-134.
64. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, et al. (2008) Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 359:355-365.
65. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, and Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
66. Court MH (2010) Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 42:209-224.
67. Crane HM, Kestenbaum B, Harrington RD, and Kitahata MM (2007) Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 21:1431-1439.
68. Créput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, and Nochy D (2003) Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 17:935-937.
69. Cressey TR and Lallemant M (2007) Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect Genet Evol 7:333-342.
70. Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, and Buclin T (2003) Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 73:20-30.
71. Cullen BR (1993) Does HIV-1 Tat induce a change in viral initiation rights? Cell 73:417-420.
72. Cullen BR (1998) HIV-1 auxiliary proteins: making connections in a dying cell. Cell 93:685-692.
73. Cullen BR (2003) Nuclear mRNA export: insights from virology. Trends Biochem Sci 28:419-424.
74. Dallas S, Ronaldson PT, Bendayan M, and Bendayan R (2004) Multidrug resistance protein 1-mediated transport of saquinavir by microglia. Neuroreport 15:1183-1186.
75. Damond F, Worobey M, Campa P, Farfara I, Colin G, Matheron S, Brun-Vézinet F, Robertson DL, and Simon F (2004) Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. AIDS Res Hum Retroviruses 20:666-672.
76. De Clercq E (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 38:153-179.
77. de la Tribonnière X, Broly F, Deuffic-Burban S, Bocket L, Ajana F, Viget N, Melliez H, Mouton Y, and Yazdanpanah Y (2008) ABCB1 allele polymorphism is associated with virological efficacy in naïve HIV-infected patients on HAART containing nonboosted PIs but not boosted PIs. HIV Clin Trials 9:192-201.
78. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, Wigerinck P, and de Béthune MP (2005) TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 49:2314-2321.
79. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, and Beaune PH (1990) Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387-394.
80. Dean M, Rzhetsky A, and Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11:1156-1166.
81. Debouck C, Gorniak JG, Strickler JE, Meek TD, Metcalf BW, and Rosenberg M (1987) Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci USA 84:8903-8906.
82. Delelis O, Thierry S, Subra F, Simon F, Malet I, Alloui C, Sayon S, Calvez V, Deprez E, Marcelin AG, et al. (2010) Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother 54: 491-501.
83. Descamps D, Chaix ML, Montes B, Pakianather S, Charpentier C, Storto A, Barin F, Dos Santos G, Krivine A, Delaugerre C, et al. (2010) Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother 65:2620-2627.
84. Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, Flockhart DA, and Zanger UM (2007) Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8:547-558.
85. Desta Z, Soukhova NV, and Flockhart DA (2001) Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 45:382-392.
86. Desta Z, Zhao X, Shin JG, and Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913-958.
87. Ding X and Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149-173.
88. Donahue DA, Sloan RD, Kuhl BD, Bar-Magen T, Schader SM, and Wainberg MA (2010) Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother 54:1047-1054.
89. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, and Lamarre D (1996) Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 70:3763-3769.
90. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, and Andreeff M (1992) Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729-2734.
91. Eagling VA, Profit L, and Back DJ (1999) Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 48:543-552.
92. Eagling VA, Wiltshire H, Whitcombe IW, and Back DJ (2002) CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 32:1-17.
93. Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, and Wrighton SA (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286:1253-1259.
94. Emmelkamp JM and Rockstroh JK (2007) CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions-review of the literature. Eur J Med Res 12:409-417.
95. Ena J, Amador C, Benito C, Fenoll V, and Pasquau F (2003) Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenzcontaining regimens in HIV-infected patients. Int J STD AIDS 14:776-781.
96. Erice A, Mayers DL, Strike DG, Sannerud KJ, McCutchan FE, Henry K, and Balfour HH, Jr (1993) Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 328:1163-1165.
97. Erickson DA, Mather G, Trager WF, Levy RH, and Keirns JJ (1999) Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 27:1488-1495.
98. Estrela RC, Santoro AB, Barroso PF, Tuyama M, and Suarez-Kurtz G (2008) CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects. Clin Pharmacol Ther 84:205-207.
99. Evans DT, Serra-Moreno R, Singh RK, and Guatelli JC (2010) BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol 18:388-396.
100. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, and Lindley CM (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222-1230.
101. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, et al. (2002) Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36.
102. Feng Y, Broder CC, Kennedy PE, and Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877.
103. Fitzsimmons ME and Collins JM (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256-266.
104. Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJ, and Scheper RJ (1996) Tissue distribution of the multidrug resistance protein. Am J Pathol 148:1237-1247.
105. Ford J, Cornforth D, Hoggard PG, Cuthbertson Z, Meaden ER, Williams I, Johnson M, Daniels E, Hsyu P, Back DJ, et al. (2004) Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. Antivir Ther 9:77-84.
106. Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, Petropoulos CJ, and Huang W (2009) Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 83:11440-11446.
107. Fröhlich M, Hoffmann MM, Burhenne J, Mikus G, Weiss J, and Haefeli WE (2004) Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br J Clin Pharmacol 58:443-444.
108. Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, Tanoue N, Hamada A, and Saito H (2009) P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull 32:1588-1593.
109. Fung KL and Gottesman MM (2009) A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 1794: 860-871.
110. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, et al. (2007) Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 45:1230-1237.
111. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, and de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295-306.
112. Gillet JP, Efferth T, and Remacle J (2007) Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775:237-262.
113. Giri N, Shaik N, Pan G, Terasaki T, Mukai C, Kitagaki S, Miyakoshi N, and Elmquist WF (2008) Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metab Dispos 36:1476-1484.
114. Götte M and Wainberg MA (2000) Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. Drug Resist Updat 3:30-38.
115. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, and Kahn JO (2002) Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288:181-188.
116. Guan S, Huang M, Li X, Chen X, Chan E, and Zhou SF (2006) Intra-and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese. Pharm Res 23:1983-1990.
117. Guengerich FP (1990) Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 3:363-371.
118. Guengerich FP, Wu ZL, and Bartleson CJ (2005) Function of human cytochrome P450s: characterization of the orphans. Biochem Biophys Res Commun 338:465-469.
119. Gulnik SV, Suvorov LI, Liu B, Yu B, Anderson B, Mitsuya H, and Erickson JW (1995) Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34:9282-9287.
120. Gupta A, Zhang Y, Unadkat JD, and Mao Q (2004) HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 310:334-341.
121. Gutiérrez F, Navarro A, Padilla S, Antón R, Masiá M, Borrás J, and Martín-Hidalgo A (2005) Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 41:1648-1653.
122. Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, Rousseau F, Ingram CD, Shaw A, Lederman MM, et al. (2006) Pharmacogenetics of nevirapineassociated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 43:783-786.
123. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, and Acosta EP (2004) Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18:2391-2400.
124. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL, Jr., Donahue JP, and Kim RB (2005) Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis 192:1931-1942.
125. Hagenbuch B and Gui C (2008) Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38:778-801.
126. Hamidi M (2006) Role of P-glycoprotein in tissue uptake of indinavir in rat. Life Sci 79:991-998.
127. Hanna IH, Reed JR, Guengerich FP, and Hollenberg PF (2000) Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Arch Biochem Biophys 376:206-216.
128. Hansen AB, Mathiesen S, and Gerstoft J (2004) Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir. Scand J Infect Dis 36:389-392.
129. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, Sora ES, James CE, Gibbons S, Bray PG, et al. (2010) HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 20: 112-120.
130. Hasse B, Günthard HF, Bleiber G, and Krause M (2005) Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis 40:e22-23.
131. Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R, Martin JN, Lalezari J, Bangsberg D, Petropoulos C, et al. (2010) Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr 54:389-393.
132. Hazuda D, Iwamoto M, and Wenning L (2009) Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu Rev Pharmacol Toxicol 49:377-394.
133. He L, Vasiliou K, and Nebert DW (2009) Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics 3:195-206.
134. Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, and Bruford EA (2004) The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch 447:465-468.
135. Heeney JL, Dalgleish AG, and Weiss RA (2006) Origins of HIV and the evolution of resistance to AIDS. Science 313:462-466.
136. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28: 1176-1183.
137. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, et al. (2006) Durable efficacy of tipranavirritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368:466-475.
138. Hirani VN, Raucy JL, and Lasker JM (2004) Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos 32:1462-1467.
139. Hirt D, Mentré F, Tran A, Rey E, Auleley S, Salmon D, Duval X, Tréluyer JM, and COPHAR2-ANRS Study Group (2008) Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients. Br J Clin Pharmacol 65:548-557.
140. Ho RH and Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260-277.
141. Hochman JH, Chiba M, Yamazaki M, Tang C, and Lin JH (2001) P-glycoproteinmediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4. J Pharmacol Exp Ther 298:323-330.
142. Huang CS, Huang MJ, Lin MS, Yang SS, Teng HC, and Tang KS (2005) Genetic factors related to unconjugated hyperbilirubinemia amongst adults. Pharmacogenet Genomics 15:43-50.
143. Hugen PW, Burger DM, Brinkman K, ter Hofstede HJ, Schuurman R, Koopmans PP, and Hekster YA (2000) Carbamazepine-indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother 34:465-470.
144. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, and Schinkel AH (2002) Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16:2295-2301.
145. Hukkanen J, Väisänen T, Lassila A, Piipari R, Anttila S, Pelkonen O, Raunio H, and Hakkola J (2003) Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther 304:745-752.
146. Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, and Funae Y (1996) Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol 51: 1041-1050.
147. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, and Sugiyama Y (2007) Functional involvement of multidrug resistance-associated protein 4 (MRP4/ ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 71:619-627.
148. Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, and Mendez JC (2009) Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. AIDS Read 19:114-121.
149. Izukawa T, Nakajima M, Fujiwara R, Yamanaka H, Fukami T, Takamiya M, Aoki Y, Ikushiro S, Sakaki T, and Yokoi T (2009) Quantitative analysis of UDPglucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos 37:1759-1768.
150. Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, Valantin MA, Lechat P, and Deray AG (2006) Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 194:1481-1491.
151. Janmohamed A, Dolphin CT, Phillips IR, and Shephard EA (2001) Quantification and cellular localization of expression in human skin of genes encoding flavincontaining monooxygenases and cytochromes P450. Biochem Pharmacol 62:777-786.
152. Janneh O, Chandler B, Hartkoorn R, Kwan WS, Jenkinson C, Evans S, Back DJ, Owen A, and Khoo SH (2009) Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 64:1002-1007.
153. Janneh O, Hartkoorn RC, Jones E, Owen A, Ward SA, Davey R, Back DJ, and Khoo SH (2008) Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. Br J Pharmacol 155:875-883.
154. Janneh O, Jones E, Chandler B, Owen A, and Khoo SH (2007) Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 60:987-993.
155. Janneh O, Owen A, Chandler B, Hartkoorn RC, Hart CA, Bray PG, Ward SA, Back DJ, and Khoo SH (2005) Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 19:2097-2102.
156. Jayaraman GC, Archibald CP, Kim J, Rekart ML, Singh AE, Harmen S, Wood M, and Sandstrom P (2006) A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 42:86-90.
157. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, et al. (2008) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med 5:e158.
158. Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, and Richman DD (2010) Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 18:156-163.
159. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, and Back DJ (2001a) P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 15:1353-1358.
160. Jones K, Hoggard PG, Sales SD, Khoo S, Davey R, and Back DJ (2001b) Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 15:675-681.
161. Jorajuria S, Dereuddre-Bosquet N, Becher F, Martin S, Porcheray F, Garrigues A, Mabondzo A, Benech H, Grassi J, Orlowski S, et al. (2004) ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther 9:519-528.
162. Josephson F, Allqvist A, Janabi M, Sayi J, Aklillu E, Jande M, Mahindi M, Burhenne J, Bottiger Y, Gustafsson LL, et al. (2007) CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin Pharmacol Ther 81: 708-712.
163. Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, Stellbrink HJ, Faetkenheuer G, and Taubert D (2008) Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos 36:1616-1623.
164. Jung N and Taubert D (2009) Organic cation transporters and their roles in antiretroviral drug disposition. Expert Opin Drug Metab Toxicol 5:773-787.
165. Kaddoumi A, Choi SU, Kinman L, Whittington D, Tsai CC, Ho RJ, Anderson BD, and Unadkat JD (2007) Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. Drug Metab Dispos 35:1459-1462.
166. Kaniwa N, Kurose K, Jinno H, Tanaka-Kagawa T, Saito Y, Saeki M, Sawada J, Tohkin M, and Hasegawa R (2005) Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American. Drug Metab Dispos 33:458-465.
167. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, Legendre C, Martinez F, and Molina JM (2003) Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 36:1070-1073.
168. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner JA, and Wenning LA (2007) Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 35:1657-1663.
169. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, et al. (2006) Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313:523-526.
170. Ki CS, Lee KA, Lee SY, Kim HJ, Cho SS, Park JH, Cho S, Sohn KM, and Kim JW (2003) Haplotype structure of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and its relationship to serum total bilirubin concentration in a male Korean population. Clin Chem 49:2078-2081.
171. Kim AE, Dintaman JM, Waddell DS, and Silverman JA (1998a) Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 286: 1439-1445.
172. Kim RB (2003) Drug transporters in HIV Therapy. Top HIV Med 11:136-139.
173. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, and Wilkinson GR (1998b) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
174. Kis O, Zastre JA, Ramaswamy M, and Bendayan R (2010) pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J Pharmacol Exp Ther 334: 1009-1022.
175. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, and Fletcher CV (2008) Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr 47:298-303.
176. Kivistö KT, Bookjans G, Fromm MF, Griese EU, Münzel P, and Kroemer HK (1996) Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 42:387-389.
177. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, Schwab M, and Zanger UM (2005) Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15:861-873.
178. Klimecki WT, Futscher BW, Grogan TM, and Dalton WS (1994) P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83:2451-2458.
179. Koch I, Weil R, Wolbold R, Brockmöller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, et al. (2002) Interindividual variability and tissuespecificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114.
180. Köck K, Grube M, Jedlitschky G, Oevermann L, Siegmund W, Ritter CA, and Kroemer HK (2007) Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin Pharmacokinet 46:449-470.
181. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, and Sigal IS (1988) Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 85:4686-4690.
182. Kohlrausch FB, de Cássia Estrela R, Barroso PF, and Suarez-Kurtz G (2010) The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol 69:95-98.
183. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
184. König J, Cui Y, Nies AT, and Keppler D (2000) A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278:G156-G164.
185. König J, Seithel A, Gradhand U, and Fromm MF (2006) Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 372:432-443.
186. König SK, Herzog M, Theile D, Zembruski N, Haefeli WE, and Weiss J (2010) Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 65:2319-2328.
187. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J, and Gerber N (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26:552-561.
188. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
189. Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, and Granneman GR (1999) Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos 27:902-908.
190. Kumar GN, Rodrigues AD, Buko AM, and Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423-431.
191. Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, and Krähenbühl S (1998) Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 45:355-359.
192. Kwan WS, Janneh O, Hartkoorn R, Chandler B, Khoo S, Back D, and Owen A (2009) Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. Br J Clin Pharmacol 68:375-380.
193. Kwara A, Lartey M, Boamah I, Rezk NL, Oliver-Commey J, Kenu E, Kashuba AD, and Court MH (2009a) Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol 49:1079-1090.
194. Kwara A, Lartey M, Sagoe KW, Kenu E, and Court MH (2009b) CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23:2101-2106.
195. Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
196. Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M, Schwab M, and Zanger UM (2004) Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 311:34-43.
197. Langmann P, Winzer R, Schirmer D, Heinz W, Leyh M, Guhl C, Weissbrich B, and Klinker H (2008) Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring. Eur J Med Res 13:469-471.
198. Le Tiec C, Barrail A, Goujard C, and Taburet AM (2005) Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 44: 1035-1050.
199. Lee AM, Miksys S, Palmour R, and Tyndale RF (2006) CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment. Neuropharmacology 50:441-450.
200. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, and Dey S (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601.
201. Lee JC and Marosok RD (2003) Acute tubular necrosis in a patient receiving tenofovir. AIDS 17:2543-2544.
202. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, Mohrenweiser HW, and Goldstein JA (2003) Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13:461-472.
203. Leschziner GD, Andrew T, Pirmohamed M, and Johnson MR (2007) ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 7:154-179.
204. Leung S and Bendayan R (2001) Uptake properties of lamivudine (3TC) by a continuous renal epithelial cell line. Can J Physiol Pharmacol 79:59-66.
205. Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, and Oshiro LS (1984) Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 225:840-842.
206. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, et al. (2011) Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305:1327-1335.
207. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, et al. (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347:385-394.
208. Lowenhaupt EA, Matson K, Qureishi B, Saitoh A, and Pugatch D (2007) Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz. Clin Infect Dis 45:e128-130.
209. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, and Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22:947-955.
210. Lubomirov R, Colombo S, di Iulio J, Ledergerber B, Martinez R, Cavassini M, Hirschel B, Bernasconi E, Elzi L, Vernazza P, et al. (2011) Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis 203:246-257.
211. Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, Furrer H, Vernazza P, Calmy A, Cavassini M, et al. (2010) ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 20:217-230.
212. Ludescher C, Pall G, Irschick EU, and Gastl G (1998) Differential activity of P-glycoprotein in normal blood lymphocyte subsets. Br J Haematol 101:722-727.
213. Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, Venuto CS, Slish JC, DiFrancesco R, Forrest A, et al. (2007) Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics 8:227-235.
214. MacArthur RD and Novak RM (2008) Review of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 47:236-241.
215. MacGregor TR, Sabo JP, Norris SH, Johnson P, Galitz L, and McCallister S (2004) Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin Trials 5:371-382.
216. Maffeo A, Bellomi F, Solimeo I, Bambacioni F, Scagnolari C, De Pisa F, Dupuis ML, Cianfriglia M, Antonelli G, and Turriziani O (2004) P-glycoprotein expression affects the intracellular concentration and antiviral activity of the protease inhibitor saquinavir in a T cell line. New Microbiol 27:119-126.
217. Mahungu T, Smith C, Turner F, Egan D, Youle M, Johnson M, Khoo S, Back Dj, and Owen A (2009a) Cytochrome P450 2B6 516G->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med 10:310-317.
218. Mahungu TW, Rodger AJ, and Johnson MA (2009b) HIV as a chronic disease. Clin Med 9:125-128.
219. Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, et al. (2008) Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 52:1351-1358.
220. Mallants R, Van Oosterwyck K, Van Vaeck L, Mols R, De Clercq E, and Augustijns P (2005) Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica 35:1055-1066.
221. Mao Q and Unadkat JD (2005) Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7:E118-133.
222. Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, et al. (2001) Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 15:1261-1268.
223. Marzolini C, Paus E, Buclin T, and Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13-33.
224. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, and Buclin T (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75.
225. Masiá M, Gutiérrez F, Padilla S, Ramos JM, and Pascual J (2005) Severe toxicity associated with the combination of tenofovir and didanosine: case report and review. Int J STD AIDS 16:646-648.
226. Mathiesen S, Justesen US, Von Lüttichau HR, and Hansen AB (2006) Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects. Scand J Infect Dis 38:733-735.
227. Mauss S, Berger F, and Schmutz G (2005) Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 19:93-95.
228. Meaden ER, Hoggard PG, Newton P, Tjia JF, Aldam D, Cornforth D, Lloyd J, Williams I, Back DJ, and Khoo SH (2002) P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother 50:583-588.
229. Mehlotra RK, Bockarie MJ, and Zimmerman PA (2007) CYP2B6 983T_C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br J Clin Pharmacol 64:391-395.
230. Mehlotra RK, Ziats MN, Bockarie MJ, and Zimmerman PA (2006) Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol 62:267-275.
231. Mertz D, Battegay M, Marzolini C, and Mayr M (2009) Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. Am J Kidney Dis 54:e1-4.
232. Miksys S, Lerman C, Shields PG, Mash DC, and Tyndale RF (2003) Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45:122-132.
233. Miller V, de Béthune MP, Kober A, Stürmer M, Hertogs K, Pauwels R, Stoffels P, and Staszewski S (1998) Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother 42:3123-3129.
234. Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P, Clotet B, Pastor-Anglada M, Koepsell H, and Martinez-Picado J (2009) Transport of lamivudine [(-)-β-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther 329:252-261.
235. Mo SL, Liu YH, Duan W, Wei MQ, Kanwar JR, and Zhou SF (2009) Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab 10:730-753.
236. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, et al. (1998) A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 279:930-937.
237. Moore KH, Yuen GJ, Raasch RH, Eron JJ, Martin D, Mydlow PK, and Hussey EK (1996) Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 59:550-558.
238. Moss DM, Kwan WS, Liptrott NJ, Smith DL, Siccardi M, Khoo SH, Back DJ, and Owen A (2011) Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 55:879-887.
239. Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, and Watkins PB (2005) Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther 78:605-618.
240. Mutlib AE, Chen H, Nemeth GA, Markwalder JA, Seitz SP, Gan LS, and Christ DD (1999) Identification and characterization of efavirenz metabolites by liquid chromatography/ mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 27:1319-1333.
241. Nascimbeni M, Lamotte C, Peytavin G, Farinotti R, and Clavel F (1999) Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother 43:2629-2634.
242. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, et al. (2007) The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21:1273-1281.
243. Ocwieja KE, Brady TL, Ronen K, Huegel A, Roth SL, Schaller T, James LC, Towers GJ, Young JA, Chanda SK, König R, Malani N, Berry CC, and Bushman FD. (2011) HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2. PLoS Pathog 7:e1001313.
244. Ortiz de Montellano PR (2005) Cytochrome P450: Structure, Mechanism, and Biochemistry. Kluwer Academic/Plenum Publishers, New York.
245. Oselin K, Mrozikiewicz PM, Pähkla R, and Roots I (2003) Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+ cells. Eur J Haematol 71:119-123.
246. Owen A, Pirmohamed M, Khoo SH, and Back DJ (2006) Pharmacogenetics of HIV therapy. Pharmacogenet Genomics 16:693-703.
247. Padilla S, Gutiérrez F, Masiá M, Cánovas V, and Orozco C (2005) Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. AIDS Patient Care STDS 19:421-424.
248. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34:880-886.
249. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
250. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, and Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860.
251. Pan G, Giri N, and Elmquist WF (2007) Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos 35:1165-1173.
252. Park S and Sinko PJ (2005) P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J Pharmacol Exp Ther 312:1249-1256.
253. Park WB, Choe PG, Song KH, Jeon JH, Park SW, Kim HB, Kim NJ, Oh MD, and Choe KW (2010) Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency. Clin Infect Dis 51:101-106.
254. Pertel T, Hausmann S, Morger D, Züger S, Guerra J, Lascano J, Reinhard C, Santoni FA, Uchil PD, Chatel L, et al. (2011) TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472:361-365.
255. Phillips EJ and Mallal SA (2008) Pharmacogenetics and the potential for the individualization of antiretroviral therapy. Curr Opin Infect Dis 21:16-24.
256. Pillay D (2004) Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther 9:695-702.
257. Ping LH, Nelson JA, Hoffman IF, Schock J, Lamers SL, Goodman M, Vernazza P, Kazembe P, Maida M, Zimba D, Goodenow MM, Eron JJ, Jr., Fiscus SA, Cohen MS, and Swanstrom R (1999) Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol 73:6271-6281.
258. Plosker GL and Noble S (1999) Indinavir: a review of its use in the management of HIV infection. Drugs 58:1165-1203.
259. Popovic M, Sarngadharan MG, Read E, and Gallo RC (1984) Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500.
260. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, Walker AS, and CASCADE Collaboration (2003) Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362:1267-1274.
261. Quaranta S, Chevalier D, Allorge D, Lo-Guidice JM, Migot-Nabias F, Kenani A, Imbenotte M, Broly F, Lacarelle B, and Lhermitte M (2006) Ethnic differences in the distribution of CYP3A5 gene polymorphisms. Xenobiotica 36:1191-1200.
262. Raunio H, Hakkola J, Hukkanen J, Lassila A, Päivärinta K, Pelkonen O, Anttila S, Piipari R, Boobis A, and Edwards RJ (1999) Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Exp Toxicol Pathol 51:412-417.
263. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, Wieman LM, Eisenberg EJ, and Rhodes GR (2006) Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 50:3297-3304.
264. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, and Borst P (2003) Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 63: 1094-1103.
265. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448.
266. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, and Shafer RW (2003) Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31:298-303.
267. Ridky T and Leis J (1995) Development of drug resistance to HIV-1 protease inhibitors. J Biol Chem 270:29621-29623.
268. Rifkin BS and Perazella MA (2004) Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 117:282-284.
269. Ritchie MD, Haas DW, Motsinger AA, Donahue JP, Erdem H, Raffanti S, Rebeiro P, George AL, Kim RB, Haines JL, et al. (2006) Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 43:779-782.
270. Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, and Penzak SR (2008) Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 49:513-519.
271. Rodríguez-Nóvoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, Cuenca L, González-Pardo G, Khoo S, Back D, et al. (2009) Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 48:e108-116.
272. Rodríguez-Nóvoa S, Martín-Carbonero L, Barreiro P, González-Pardo G, Jiménez-Nácher I, González-Lahoz J, and Soriano V (2007) Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 21:41-46.
273. Rodríguez Nóvoa S, Barreiro P, Rendón A, Barrios A, Corral A, Jiménez-Nacher I, González-Lahoz J, and Soriano V (2006) Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 42:291-295.
274. Romani B, Engelbrecht S, and Glashoff RH (2010) Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J Gen Virol 91:1-12.
275. Ronaldson PT, Lee G, Dallas S, and Bendayan R (2004) Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. Pharm Res 21:811-818.
276. Ross L, Lim ML, Liao Q, Wine B, Rodriguez AE, Weinberg W, and Shaefer M (2007) Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities. HIV Clin Trials 8:1-8.
277. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Décosterd L, Telenti A, et al. (2005a) Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 15:1-5.
278. Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, Vernazza P, Drechsler H, Bernasconi E, Rickenbach M, Telenti A, et al. (2005b) Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 192:1381-1386.
279. Roucairol C, Azoulay S, Nevers MC, Créminon C, Lavrut T, Garraffo R, Grassi J, Burger A, and Duval D (2007) Quantitative immunoassay to measure plasma and intracellular atazanavir levels: analysis of drug accumulation in cultured T cells. Antimicrob Agents Chemother 51:405-411.
280. Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, et al. (2010) CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 54:285-289.
281. Sakaeda T, Nakamura T, and Okumura K (2003) Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4:397-410.
282. Salama NN, Kelly EJ, Bui T, and Ho RJ (2005) The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice. J Pharm Sci 94:1216-1225.
283. Sankatsing SU, Beijnen JH, Schinkel AH, Lange JM, and Prins JM (2004) P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother 48:1073-1081.
284. Santiago ML, Range F, Keele BF, Li Y, Bailes E, Bibollet-Ruche F, Fruteau C, Noë R, Peeters M, Brookfield JF, et al. (2005) Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Taï Forest, Côte d'Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2. J Virol 79:12515-12527.
285. Saumoy M, Vidal F, Peraire J, Sauleda S, Vea AM, Viladés C, Ribera E, and Richart C (2004) Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS 18:1741-1742.
286. Schaaf B, Aries SP, Kramme E, Steinhoff J, and Dalhoff K (2003) Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 37:e41-43.
287. Schiller DS and Youssef-Bessler M (2009) Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTIresistant strains of HIV. Clin Ther 31:692-704.
288. Schinkel AH and Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29.
289. Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, Davies G, Khoo S, Fätkenheuer G, Youle M, et al. (2011) Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J Antimicrob Chemother 66:1332-1339.
290. Schmitt C, Hofmann C, Riek M, Patel A, and Zwanziger E (2009) Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy 29:1175-1181.
291. Schöller-Gyüre M, Kakuda TN, De Smedt G, Vanaken H, Bouche MP, Peeters M, Woodfall B, and Hoetelmans RM (2008) A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol 66:508-516.
292. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, and Fridland A (1999) MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5:1048-1051.
293. Seminari E, Castagna A, and Lazzarin A (2008) Etravirine for the treatment of HIV infection. Expert Rev Anti Infect Ther 6:427-433.
294. Shafer RW (2002) Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 15:247-277.
295. Shafer RW (2006) Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194 (Suppl 1):S51-S58.
296. Shaik N, Giri N, Pan G, and Elmquist WF (2007) P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos 35:2076-2085.
297. Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, Jean-Pierre P, Hogan C, Simon V, Boden D, et al. (2006) Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 41:439-446.
298. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
299. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, and Ingelman-Sundberg M(2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113.
300. Sloan RD, Donahue DA, Kuhl BD, Bar-Magen T, and Wainberg MA (2010) Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes. Retrovirology 7:44.
301. Sloan RD, Kuhl BD, Donahue DA, Roland A, Bar-Magen T, and Wainberg MA (2011) Transcription of preintegrated HIV-1 cDNA modulates cell surface expression of major histocompatibility complex class I via Nef. J Virol 85:2828-2836.
302. Solas C, Simon N, Drogoul MP, Quaranta S, Frixon-Marin V, Bourgarel-Rey V, Brunet C, Gastaut JA, Durand A, Lacarelle B, et al. (2007) Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br J Clin Pharmacol 64:353-362.
303. Srinivas RV, Middlemas D, Flynn P, and Fridland A (1998) Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 42:3157-3162.
304. St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, Meier PJ, and Marin JJ (2000) Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 279:R1495-1503.
305. Ståhle L, Moberg L, Svensson JO, and Sönnerborg A (2004) Efavirenz plasma concentrations in HIV-infected patients: inter-and intraindividual variability and clinical effects. Ther Drug Monit 26:267-270.
306. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, et al. (1999) Efavirenz plus zidovu-dine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 341:1865-1873.
307. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, and Mayers DL (2003) A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 34 (Suppl 1):S21-S33.
308. Storch CH, Theile D, Lindenmaier H, Haefeli WE, and Weiss J (2007) Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 73:1573-1581.
309. Stresser DM and Kupfer D (1999) Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab Dispos 27:517-525.
310. Su Y, Zhang X, and Sinko PJ (2004) Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm 1:49-56.
311. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, and Moore RD (2002) Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35:182-189.
312. Takeuchi K, Kobayashi Y, Tamaki S, Ishihara T, Maruo Y, Araki J, Mifuji R, Itani T, Kuroda M, Sato H, et al. (2004) Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects. J Gastroenterol Hepatol 19:1023-1028.
313. Takubo T, Kato T, Kinami J, Hanada K, and Ogata H (2002) Uptake of lamivudine by rat renal brush border membrane vesicles. J Pharm Pharmacol 54:111-117.
314. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738.
315. Trapnell CB, Klecker RW, Jamis-Dow C, and Collins JM (1998) Glucuronidation of 3'-azido-3'-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob Agents Chemother 42:1592-1596.
316. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, and Oka S (2004) Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319:1322-1326.
317. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
318. Turner D, Brenner B, and Wainberg MA (2003) Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1. Clin Diagn Lab Immunol 10:979-981.
319. Turner D and Wainberg MA (2006) HIV transmission and primary drug resistance. AIDS Rev 8:17-23.
320. Turriziani O, Gianotti N, Falasca F, Boni A, Vestri AR, Zoccoli A, Lazzarin A, and Antonelli G (2008) Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. J Med Virol 80:766-771.
321. Urawa N, Kobayashi Y, Araki J, Sugimoto R, Iwasa M, Kaito M, and Adachi Y (2006) Linkage disequilibrium of UGT1A1 *6 and UGT1A1 *28 in relation to UGT1A6 and UGT1A7 polymorphisms. Oncol Rep 16:801-806.
322. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, and Russel FG (2002) The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13:595-603.
323. Van Aubel RA, Smeets PH, van den Heuvel JJ, and Russel FG (2005) Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 288:F327-333.
324. van der Sandt IC, Vos CM, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boer AG, and Breimer DD (2001) Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS 15:483-491.
325. van Gelder J, Deferme S, Naesens L, De Clercq E, van den Mooter G, Kinget R, and Augustijns P (2002) Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos 30:924-930.
326. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, et al. (2004) Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363:1253-1263.
327. Van Maele B, Busschots K, Vandekerckhove L, Christ F, and Debyser Z (2006) Cellular co-factors of HIV-1 integration. Trends Biochem Sci 31:98-105.
328. van Waterschoot RA, ter Heine R, Wagenaar E, van der Kruijssen CM, Rooswinkel RW, Huitema AD, Beijnen JH, and Schinkel AH (2010) Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 160:1224-1233.
329. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, Kücherer C, Struck D, Schmit JC, Asjö B, et al. (2009) Transmission of drugresistant HIV-1 is stabilizing in Europe. J Infect Dis 200:1503-1508.
330. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, Ronco P, and Rossert J (2002) Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 40:1331-1333.
331. Vilmer E, Barre-Sinoussi F, Rouzioux C, Gazengel C, Brun FV, Dauguet C, Fischer A, Manigne P, Chermann JC, Griscelli C, et al. (1984) Isolation of new lymphotropic retrovirus from two siblings with haemophilia B, one with AIDS. Lancet 1:753-757.
332. Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D, Andries K, Pauwels R, and de Béthune MP (2005) TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 79:12773-12782.
333. Vourvahis M and Kashuba AD (2007) Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 27:888-909.
334. Wainberg MA (2004) The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther 2:147-151.
335. Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, and Smith DA (2005) Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 33:587-595.
336. Wang H and Tompkins LM (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9:598-610.
337. Wang J, Sönnerborg A, Rane A, Josephson F, Lundgren S, Ståhle L, and Ingelman-Sundberg M (2006) Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 16:191-198.
338. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, and Baba M (2003) Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol 63:65-72.
339. Wang X, Nitanda T, Shi M, Okamoto M, Furukawa T, Sugimoto Y, Akiyama S, and Baba M (2004) Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Biochem Pharmacol 68:1363-1370.
340. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, and Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306: 287-300.
341. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM, Jr., LaLota M, Dickinson G, Schwarcz S, Torian L, Wendell D, Paul S, Goza GA, Ruiz J, Boyett B, and Kaplan JE (2004) The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189:2174-2180.
342. Weiss J, Herzog M, König S, Storch CH, Ketabi-Kiyanvash N, and Haefeli WE (2009) Induction of multiple drug transporters by efavirenz. J Pharmacol Sci 109:242-250.
343. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, and Efferth T (2007a) Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59:238-245.
344. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, and Haefeli WE (2007b) Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 35:340-344.
345. Weiss RA (2002) HIV receptors and cellular tropism. IUBMB Life 53:201-205.
346. Weiss RA (2008) Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges. Clin Exp Immunol 152:201-210.
347. Wensing AM, van de Vijver DA, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, et al. (2005) Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 192:958-966.
348. Williams GC, Liu A, Knipp G, and Sinko PJ (2002) Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother 46:3456-3462.
349. Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M, and Zanger UM (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-988.
350. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, Edwards SG, Johnson MA, and Connolly JO (2009) Tenofovir-associated renal and bone toxicity. HIV Med 10:482-487.
351. World Health Organization (2011) Global Report UNAIDS Report on the Global AIDS Epidemic 2010. World Health Organization, Geneva, Switzerland. Available at http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf.
352. Wu Y (2004) HIV-1 gene expression: lessons from provirus and non-integrated DNA. Retrovirology 1:13.
353. Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, et al. (2011) Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother 66: 2092-2098.
354. Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, Bogner JR, Rockstroh J, Esser S, Jaeger H, et al. (2008) Impact of CYP2B6 983T_C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 61:914-918.
355. Xie HG, Wood AJ, Kim RB, Stein CM, and Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.
356. Yamakoshi Y, Kishimoto T, Sugimura K, and Kawashima H (1999) Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun 260:676-681.
357. Yamamoto K, Sato H, Fujiyama Y, Doida Y, and Bamba T (1998) Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II. Biochim Biophys Acta 1406:267-273.
358. Yeni P (2003) Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J Acquir Immune Defic Syndr 34 (Suppl 1):S91-S94.
359. Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, Suda A, Worku A, Haefeli WE, Burhenne J, Aderaye G, et al. (2011) High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J. http//dx.doi.org/10.1038/tpj.2011.34.
360. Yuen GJ, Weller S, and Pakes GE (2008) A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 47:351-371.
361. Zaitseva L, Cherepanov P, Leyens L, Wilson SJ, Rasaiyaah J, and Fassati A (2009) HIV-1 exploits importin 7 to maximize nuclear import of its DNA genome. Retrovirology 6:11.
362. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, and Schwab M(2007) Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8:743-759.
363. Zastre JA, Chan GN, Ronaldson PT, Ramaswamy M, Couraud PO, Romero IA, Weksler B, Bendayan M, and Bendayan R (2009) Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res 87:1023-1036.
364. Zhang J, Alston MA, Huang H, and Rabin RL (2006) Human T cell cytokine responses are dependent on multidrug resistance protein-1. Int Immunol 18:485-493.
365. Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, and Giacomini KM (2000) Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos 28:329-334.
366. Zhu M, Kaul S, Nandy P, Grasela DM, and Pfister M (2009) Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob Agents Chemother 53:2346-2353.
367. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, and Braden G (2006) Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 42:283-290.
368. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, Kearney BP, and Cheng AK (2010) Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, doseranging clinical trial. J Infect Dis 201:814-822.
369. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, Feinberg J, and Sherman KE (2001) Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 98:12671-12676.